Matt Miksic
Stock Analyst at Barclays
(3.79)
# 721
Out of 5,113 analysts
319
Total ratings
58.23%
Success rate
5.94%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Downgrades: Underweight | $80 → $71 | $72.86 | -2.55% | 9 | Jan 12, 2026 | |
| EW Edwards Lifesciences | Maintains: Overweight | $103 → $104 | $83.66 | +24.31% | 32 | Jan 12, 2026 | |
| PODD Insulet | Downgrades: Underweight | $316 → $274 | $271.60 | +0.88% | 12 | Jan 12, 2026 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $11 → $12 | $4.04 | +197.03% | 4 | Jan 9, 2026 | |
| LIVN LivaNova | Maintains: Equal-Weight | $58 → $67 | $63.16 | +6.08% | 9 | Jan 9, 2026 | |
| BAX Baxter International | Maintains: Overweight | $36 → $30 | $19.84 | +51.21% | 23 | Jan 9, 2026 | |
| MDT Medtronic | Maintains: Overweight | $111 → $116 | $100.88 | +14.99% | 23 | Jan 8, 2026 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $635 → $686 | $523.99 | +30.92% | 8 | Jan 7, 2026 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $23 → $27 | $15.62 | +72.86% | 5 | Jan 7, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $162 → $169 | $107.42 | +57.33% | 31 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $197 → $217 | $220.14 | -1.43% | 15 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $55 | $19.90 | +176.38% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $106 → $114 | $92.52 | +23.22% | 16 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $105 → $104 | $86.60 | +20.09% | 9 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1.5 → $31 | $7.31 | +324.08% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $16.98 | +0.12% | 6 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $355.04 | +27.59% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $79.77 | +7.81% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $85 | $81.29 | +4.56% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $80.29 | +7.11% | 10 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $136 | $92.51 | +47.01% | 19 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $1.05 | +233.33% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $13.95 | +50.54% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $201.79 | +19.43% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $6.46 | +240.56% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $77.21 | +29.52% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $168.73 | +147.73% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $18.51 | +51.27% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $12.73 | +426.32% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $2.51 | +19,023.51% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $11.90 | +631.09% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $3.92 | +537.76% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $5.26 | +71.10% | 1 | Dec 12, 2016 |
DexCom
Jan 12, 2026
Downgrades: Underweight
Price Target: $80 → $71
Current: $72.86
Upside: -2.55%
Edwards Lifesciences
Jan 12, 2026
Maintains: Overweight
Price Target: $103 → $104
Current: $83.66
Upside: +24.31%
Insulet
Jan 12, 2026
Downgrades: Underweight
Price Target: $316 → $274
Current: $271.60
Upside: +0.88%
Orchestra BioMed Holdings
Jan 9, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $4.04
Upside: +197.03%
LivaNova
Jan 9, 2026
Maintains: Equal-Weight
Price Target: $58 → $67
Current: $63.16
Upside: +6.08%
Baxter International
Jan 9, 2026
Maintains: Overweight
Price Target: $36 → $30
Current: $19.84
Upside: +51.21%
Medtronic
Jan 8, 2026
Maintains: Overweight
Price Target: $111 → $116
Current: $100.88
Upside: +14.99%
Intuitive Surgical
Jan 7, 2026
Maintains: Overweight
Price Target: $635 → $686
Current: $523.99
Upside: +30.92%
Alphatec Holdings
Jan 7, 2026
Maintains: Overweight
Price Target: $23 → $27
Current: $15.62
Upside: +72.86%
Abbott Laboratories
Jan 5, 2026
Maintains: Overweight
Price Target: $162 → $169
Current: $107.42
Upside: +57.33%
Dec 30, 2025
Maintains: Equal-Weight
Price Target: $197 → $217
Current: $220.14
Upside: -1.43%
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $19.90
Upside: +176.38%
Nov 10, 2025
Maintains: Overweight
Price Target: $106 → $114
Current: $92.52
Upside: +23.22%
Nov 6, 2025
Maintains: Underweight
Price Target: $105 → $104
Current: $86.60
Upside: +20.09%
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $7.31
Upside: +324.08%
Oct 31, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $16.98
Upside: +0.12%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $355.04
Upside: +27.59%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $79.77
Upside: +7.81%
Oct 13, 2025
Initiates: Overweight
Price Target: $85
Current: $81.29
Upside: +4.56%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $80.29
Upside: +7.11%
Oct 2, 2025
Maintains: Overweight
Price Target: $133 → $136
Current: $92.51
Upside: +47.01%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.05
Upside: +233.33%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $13.95
Upside: +50.54%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $201.79
Upside: +19.43%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $6.46
Upside: +240.56%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $77.21
Upside: +29.52%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $168.73
Upside: +147.73%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $18.51
Upside: +51.27%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $12.73
Upside: +426.32%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $2.51
Upside: +19,023.51%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $11.90
Upside: +631.09%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $3.92
Upside: +537.76%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $5.26
Upside: +71.10%